Dietary supplements and natural products as psychotherapeutic agents

Psychosomatic Medicine

Volumn 61, Issue 5, 1999, Pages 712-728

  Fugh Berman, Adriane ^a   Cott, Jerry M ^b  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Dietary supplements; Ginkgo biloba; Kava; Omega 3 fatty acids; St. John's wort; Vitamins

Indexed keywords

DOCOSAHEXAENOIC ACID; FOLIC ACID; KAVA; OMEGA 3 FATTY ACID; PHENYLALANINE; S ADENOSYLMETHIONINE; TRYPTOPHAN; VALERIAN;

ANXIETY; ARTICLE; DEMENTIA; DIET SUPPLEMENTATION; GINKGO BILOBA; HUMAN; HYPERICUM PERFORATUM; INSOMNIA; MEMORY; MOOD; PHYTOTHERAPY; PRIORITY JOURNAL;

EID: 0032878861     PISSN: 00333174     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006842-199909000-00012     Document Type: Article

References (173)

1. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States: prevalence, costs, and patterns of use. N Engl J Med 1993;328:246-52.
2. Astin JA. Why patients use alternative medicine: results of a national study. JAMA 1998;279:1548-53.
3. Emmanuel NP, Cosby C, Crawford M, Mintzer O-B, Book S, Kapp R, Morton A, Johnson M, Lorberbaum J, Jones C, Lydiard RB. Prevalence of herbal products use by subjects evaluated for pharmacological clinical trials. Presented at the 38th Annual Meeting of the New Clinical Drug Evaluation Unit Program, Boca Raton, FL; June 10-13, 1998.
4. Landes P. Market report. HerbalGram 1998;42:64-5.
5. Rosenthal NE. St. John's wort: the herbal way to feeling good. New York: Harper Collins; 1998.
6. Cass H. St. John's wort: nature's blues buster. Garden City Park, NY: Avery Publishing Group; 1998.
7. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St. John's wort for depression - an overview and meta-analysis of randomized clinical trials. BMJ 1996;313:253-8.
8. Wheatley D. LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients - a controlled 6-week clinical trial. Pharmacopsychiatry 1977;30(Suppl 2):77-80.
9. Vorbach EU, Amoldt KH, Hubner WD. Efficacy and tolerability of St. John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Pharmacopsychiatry 1997;30(Suppl 2):81-5.
10. Müller WE, Rolli M, Schäfer C, Hafner U. Effects of Hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry 1997;30(Suppl 2):102-7.
11. Cott JM. In vitro receptor binding and enzyme inhibition by Hypericum perforation extract. Pharmacopsychiatry 1997;30(suppl 2):108-12.
12. Laakman G, Schüle C, Baghai T, Kieser M. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 1998;31(suppl):54-9.
13. Brockmöller J, Reum T, Bauer S, Kerb R, Hubner WD, Roots I. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 1997;30(Suppl 2):94-101.
14. Anderson R, Flynn N, Jain S, Samuels S, Perkins C, Enders S. Testing is not enough: do IDU know their serostatus? Abstract, Proceedings of the VIII International Conference on AIDS, Amsterdam; 1992.
15. Gordon JB. SSRIs and St. John's wort: possible toxicity? Am Earn Physician 1998;57:950, 953.
16. Tran TL. A dynamic ileus associated with the use of St. John's wort. Curr Clin Strategies 1997;125:1022-87.
17. Demott K. St. Johnswort tied to serotonin syndrome. Clin Psychiatr News 1998;26:28.
18. Bove GM. Acute neuropathy after exposure to sun in a patient treated with St John's wort. Lancet 1998;352:1121-2.
19. Garrett BJ, Cheeke PR, Miranda CL, Goeger DE, Buhler DR. Consumption of poisonous plants (Senecio jacobaea, Symphytum officinale, Pteridium aquilinum, Hypericum perforatum) by rats: chronic toxicity, mineral metabolism, and hepatic drug-metabolizing enzymes. Toxicol Lett 1982;10:183-8.
20. Leuschner J. Preclinical toxicological profile of Hypericum extract LI 160. Presented at the Second International Congress on Phytomedicine, Munich; September 1996. Abstract SL-80.
21. DeFeudis FV. Ginkgo biloba extract (EGb 761): from chemistry to the clinic. Wiesbaden, Germany: Ullstein Medical; 1998.
22. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 1997;278:1327-32.
23. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-91.
24. Kanowski S, Herrmann WM, Stephan K, Wierich W, Hoerr R. Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 1996;29:47-56.
25. Hofferberth B. The efficacy of Egb 761 in patients with senile dementia of the Alzheimer type: a double-blind, placebo-controlled study on different levels of investigation. Hum Psychopharmacol 1994;9:215-22.
26. Rai GS, Shovlin C, Wesnes KA. A double-blind, placebo-controlled study of Ginkgo biloba extract ('Tanakan') in elderly outpatients with mild to moderate memory impairment. Curr Med Res Opin 1991;12:350-5.
27. Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 1998;55:1409-15.
28. Kleijnen J, Knipschild P. Ginkgo biloba for cerebral insufficiency. Br J Clin Pharmacol 1992;34:352-8.
29. Kleijnen J, Knipschild P. Ginkgo biloba. Lancet 1992;340:1136-9.
30. Itil T, Martorano D. Natural substances in psychiatry (Ginkgo biloba in dementia). Psychopharmacol Bull 1995;31:147-58.
31. Itil TM, Eralp E, Tsambis E, Itil KZ, Stein U. Central nervous system effects of Ginkgo biloba, a plant extract. Am J Ther 1996;3:63-73.
32. Larsen RG, Dupeyron JP, Boulu RG. An experimental model of cerebral ischemia induced by microspheres in the rat: effect of 2 Ginkgo biloba extracts and of naftidrofuryl [in French]. Therapie 1978;33:651-60.
33. Karcher L, Zagermann P, Krieglstein J. Effect of an extract of Ginkgo biloba on rat brain energy metabolism in hypoxia. Naunyn Schmiedebergs Arch Pharmacol 1984;327:31-5.
34. Panetta T, Marcheselli VL, Braquet P, Spinnewyn B, Bazan NG. Effects of a platelet activating factor antagonist (BN 52021) on free fatty acids, diacylglycerols, polyphosphoinositides and blood flow in the gerbil brain: inhibition of ischemia-reperfusion induced cerebral injury. Biochem Biophys Res Commun 1987;149:580-7.
35. Rodriguez de Turco EB, Droy-Lefaix MT, Bazan NG. Decreased electroconvulsive shock-induced diacylglycerols and free fatty acid accumulation in the rat brain by Ginkgo biloba extract (EGb 761): selective effect in hippocampus as compared with cerebral cortex. J Neurochem 1993;61:1438-44.
36. Prehn JH, Krieglstein J. Platelet-activating factor antagonists reduce excitotoxic damage in cultured neurons from embryonic chick telencephalon and protect the rat hippocampus and neocortex from ischemic injury in vivo. J Neurosci Res 1993;34:179-88.
37. Klein J, Chatterjee SS, Loffelholz K. Phospholipid breakdown and choline release under hypoxic conditions: inhibition by bilobalide, a constituent of Ginkgo biloba. Brain Res 1997;755:347-50.
38. Le Poncin-Lafitte M, Martin P, Lespinasse P, Rapin JR. Cerebral ischemia after ligature of both carotid arteries in rats: effect of Ginkgo biloba extracts [in French]. Sem Hop 1982;58:403-6.
39. Grosdemouge C, Le Poncin-Lafitte M, Rapin JR. Protective effects of Ginkgo biloba extract on the early rupture of the hemato-encephalic barrier in the rat [in French]. Presse Med 1986;15:1502-5.
40. Ramassamy C, Clostre F, Christen Y, Costentin J. Prevention by a Ginkgo biloba extract (GBE 761) of the dopaminergic neurotoxicity of MPTP. J Pharm Pharmacol 1990;42:785-9.
41. 2+ induced decrease in synaptosomal membrane fluidity. Free Radic Res Commun 1993;19:341-50.
42. Iliff LD, Auer LM. The effect of intravenous infusion of tebonin (Ginkgo biloba) on pial arteries in cats. J Neurosurg Sci 1983;27:227-31.
43. Braquet P. Proofs of involvement of PAF-acether in various immune disorders using BN 52021 (ginkgolide B): a powerful PAF-acether antagonist isolated from Ginkgo biloba L. Adv Prostaglandin Thromboxane Leukot Res 1986;16:179-98.
44. Lamant V, Mauco G, Braquet P, Chap H, Douste-Blazy L. Inhibition of the metabolism of platelet activating factor (PAF-acether) by three specific antagonists from Ginkgo biloba. Biochem Pharmacol 1987;36:2749-52.
45. Rogue P, Malviya AN. Inhibition of protein kinase C by Ginkgo biloba extract (EGb 761). In: Christen Y, Droy-Lefaix MT, Macias-Nuñez JF, editors. Advances in Ginkgo biloba extract research. Vol 5: Effects of Ginkgo biloba extract (EGb 761) on neuronal plasticity. Paris: Elsevier; 1996. p. 1-6.
46. 2+-loaded brain neurons. Brain Res 1994;635:125-9.
47. DeFeudis FV. Ginkgo biloba extract (EGb 761): pharmacological activities and clinical applications. New York: Elsevier; 1991.
48. Richardson JS. Free radicals in the genesis of Alzheimer's disease. Ann NY Acad Sci 1993;695:73-6.
49. Anderson DK, Thomas CE. Mechanisms and role of oxygen free radicals in CNS pathology. In: Racagni G, Brunello N, Langer SZ, editors. Recent advances in the treatment of neurodegenerative disorders and cognitive dysfunction. Int Acad Biomed Drug Res 1994;7:119-24.
50. Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 1994;77:817-27.
51. Benzi G, Moretti A. Are reactive oxygen species involved in Alzheimer's disease? Neurobiol Aging 1995;16:661-74.
52. Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology 1996;46:1775-6.
53. Gilbert GJ. Ginkgo biloba. Neurology 1997;48:1137.
54. Matthews MK Jr. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology 1998;50:1933-4.
55. Vale S. Subarachnoid haemorrhage associated with Ginkgo biloba. Lancet 1998;352:36.
56. Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract. N Engl J Med 1997;336:1108.
57. Hänsel R, Keller K, Rimpler H, Schneider G, editors. Hagers Handbuch der Pharazeutischen Praxis. 5th ed. Berlin: Springer Verlag; 1993. p. 268-92.
58. Newall CA, Anderson LA, Phillipson JD. Herbal medicines: a guide for health-care professionals. London: Pharmaceutical Press; 1996. p. 239-40.
59. Schulz V, Hansel R, Tyler VE. Rational phytotherapy: a physician's guide to herbal medicine. 3re ed. Berlin: Springer-Verlag; 1998.
60. Cass H, McNally T. Kava: nature's answer to stress, anxiety, and insomnia. Rocklin, CA: Prima Health; 1998.
61. Lehmann E, Kinzler E, Friedemann J. Efficacy of a special kava extract (Piper methysticum) in patients with states of anxiety, tension, and excitedness of nonmental origin - a double-blind placebo-controlled study of four weeks treatment. Phytomedicine 1996;2:113-9.
62. Volz HP, Kieser M. Kava-kava extract WS 1490 versus placebo in anxiety disorders - a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry 1997;30:1-5.
63. Kinzler E, Kromer J, Lehmann E. Wirksamkeit eines Kava-Spezial-Extraktes bei Patienten mit Angst-, Spannungs- und Erregungszustanden nicht-psychotischer Genese. Arzneimittelforschung Drug Res 1991;41:584-8.
64. Woelk H, Kapoula O, Lehrl S, Schröter K, Weinholz P. Behandlung von Angst-Patienten. Z Allg Med 1993;69:271-7.
65. Lindenberg D, Pitule-Schodel H. D, L-Kavain in comparison with oxazepam in anxiety disorders: a double-blind study of clinical effectiveness [in German]. Fortschr Med 1990;108:49-50, 53-54.
66. Warnecke G, Pfaender H, Gerster G, Gracza E. Wirksamkeit von Kava-Kava-Extrakt beim klimakterischen Syndrom. Z Phytother 1990;11:81-6.
67. Warnecke G. Psychosomatic dysfunctions in the female climacteric: clinical effectiveness and tolerance of kava extract WS 1490 [in German]. Fortschr Med 1991;109:119-22.
68. Münte TF, Heinze HJ, Matzke M, Steitz J. Effects of oxazepam and an extract of kava roots (Piper methysticum) on event-related potentials in a word recognition task. Neuropsychobiology 1993;27:46-53.
69. + channel receptor sites. Eur J Pharmacol 1996;315:89-97.
70. Jussofie A, Schmiz A, Hiemke C. Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacol (Berl) 1994;116:469-74.
71. B and benzodiazepine binding sites in rodent brain. Pharmacol Toxicol 1992;71:120-6.
72. 3H]-Monoamine uptake inhibition properties of kava pyrones. Planta Med 1997;63:548-9.
73. Hänsel R, Keller K, Rimpler H, Schneider G, editors. Hagers Handbuch der Pharnazeutischen Praxis. 6th ed. Berlin: Springer-Verlag; 1996. p. 201-21.
74. Norton SA, Ruze P. Kava dermopathy. J Am Acad Dermatol 1994;31:89-97.
75. Ruze P. Kava-induced dermopathy: a niacin deficiency? Lancet 1990;335:1442-5.
76. Jamieson DD, Duffield PH. Positive interaction of ethanol and kava resin in mice. Clin Exp Pharmacol Physiol 1990;17:509-14.
77. Herberg KW. Effect of kava-special extract WS 1490 combined with ethyl alcohol on safety-relevant performance parameters. Blutalkohol 1993;30:96-105.
78. Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam. Ann Intern Med 1996;125:940-1.
79. Duffield PH, Jamieson D. Development of tolerance to kava in mice. Clin Exp Pharmacol Physiol 1992;18:571-8.
80. Thommessen B, Laake K. No identifiable effect of ginseng (Gericomplex) as an adjuvant in the treatment of geriatric patients. Aging Clin Exp Res 1996;8:417-20.
81. Marasco C, Ruiz V, Villagomez S, Infante B. Double-blind study of a multivitamin complex supplemented with ginseng extract. Drugs Exp Clin Res 1996;22:323-9.
82. Pearce PT, Zois I, Wynne KN, Funder JW. Panax ginseng and Eleutherococcus senticosus extracts - in vitro studies on binding to steroid receptors. Endocrinol Jpn 1982;29:567-73.
83. Hiai S, Yokoyama H, Oura H, Yano S. Stimulation of pituitary-adrenocortical system by ginseng saponin. Endocrinol Jpn 1979;26:661-5.
84. Park H-J, Rhee M-H, Park K-M, Nam KY, Park KH. Effect of nonsaponin fraction from Panax ginseng on cGMP and thromboxane A2 in human platelet aggregation. J Ethnopharmacol 1995;49:157-62.
85. Yuan CS, Attele AS, Wu JA, Liu D. Modulation of American ginseng on brainstem GABAergic effects in rats. J Ethnopharmacol 1998;62;215-22.
86. Greenspan EM. Ginseng and vaginal bleeding. JAMA 1983;249:2018.
87. Hopkins MO, Androff L, Benninghoff AS. Ginseng face cream and unexplained vaginal bleeding. Am J Obstet Gynecol 1988;159:1121-2.
88. Palmer BV, Montgomery ACV, Monteiro JCMP. Gin Seng and mastalgia. Br Med J 1978;1:1284.
89. Koriech OM. Gin Seng and mastalgia. Br Med J 1978;1:1556.
90. Shader RI, Greenblatt DJ. Phenelzine and the dream machine -ramblings and reflections. J Clin Psychopharmacol 1985;5:65.
91. Jones BD, Runikis AM. Interaction of ginseng with phenelzine. J Clin Psychopharmacol 1987;7:201-2.
92. Cui J, Garle M, Eneroth P, Björkhem I. What do commercial ginseng preparations contain? Lancet 1994;344:134.
93. Bourin M, Bougerol T, Guitton B, Broutin E. A combination of plant extracts n the treatment of outpatients with adjustment disorder with anxious mood: controlled study versus placebo. Fundam Clin Pharmacol 1997;11:127-32.
94. Wolfman C, Viola H, Paladini A, Dajas F, Medina JH. Possible anxiolytic effects of chrysin, a central benzodiazepine receptor ligand isolated from Passiflora coerulea. Pharmacol Biochem Behav 1994;47:1-4.
95. Smith GW, Chalmers TM, Nuki G. Vasculitis associated with herbal preparation containing Passiflora extract. Br J Rheumatol 1993;32:87-8.
96. European Scientific Cooperative on Phytotherapy monographs on the medicinal use of plants. Exeter, UK: European Scientific Cooperative on Phytotherapy; 1997.
97. Sopranzi N, De Feo G, Mazzanti G, Tolu L. Biological and electroencephalographic parameters in rats in relation to Passiflora incarnata L [in Italian]. Clin Ter 1990;132:329-33.
98. Mowrey DB. The scientific validation of herbal medicine. New Canaan, CT: Keats Publishing; 1986.
99. De Smet PAGM. Scutellaria species. In: De Smet PAGM, Keller K, Hänsel R, Chandler RF, editors. Adverse effects of herbal drugs, volume 2. Heidelberg, Germany: Springer-Verlag; 1993. p. 289-96.
100. De Smet PAGM. Teucrium chamaedrys. In: De Smet PAGM, Keller K, Hänsel R, Chandler RF, editors. Adverse effects of herbal drugs, volume 3. Berlin: Springer-Verlag; 1997; p. 137-44.
101. Blumenthal M. The complete German Commission E monographs: therapeutic guide to herbal medicines. Austin, TX: American Botanical Council; 1998.
102. Wagner J, Wagner ML, Hening WA. Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother 1998;32:680-91.
103. Leathwood PD, Chauffard F, Herck E, Munoz-Box R. Aqueous extract of valerian root improves sleep quality in man. Pharmacol Biochem Behav 1982;17:65-71.
104. Lindahl O, Lindwall L. Double blind study of a valerian preparation. Pharmacol Biochem Behav 1989;32:1065-6.
105. Balderer G, Borbely AA. Effect of valerian on human sleep. Psychopharmacology 1985;87:406-9.
106. Schulz H, Stolz C, Muller J. The effect of valerian extract on sleep polygraphy in poor sleepers: a pilot study. Pharmacopsychiatry 1994;27:147-51.
107. Dominguez RA, Bravo-Valverde RL, Kaplowitz BR, Cott JM. Hypnotic efficacy of valerian in Hispanic patients. Presented at the 38th Annual Meeting of the New Clinical Drug Evaluation Unit Program, Boca Raton, FL, June 10-13, 1998.
108. Kohnen R, Oswald W-D. The effects of valerian, propranolol, and their combination on activation, performance, and mood of healthy volunteers under social stress conditions. Pharmacopsychiatry 1988;21:447-8.
109. Riedel E, Hansel R, Ehrke G. Inhibition of gamma-aminobutyric acid catabolism by valerenic acid derivatives [in German], Planta Med 1982;46:219-20.
110. Mennini T, Bernasconi P, Bombardelli E, Morazzoni P. In vitro study on the interaction of extracts and pure compounds from Valeriana officinalis roots with GABA, benzodiazepine and barbiturate receptors in rat brain. Fitotherapia 1993;64:291-300.
111. 3H]GABA release in synaptosomes. Planta Med 1994;60:475-6.
112. Fehri B, Aiache JM, Boukef K, Memmi A, Hizaoui B. Valeriana officinalis and Crataegus oxyacantha: toxicity from repeated administration and pharmacologic investigations [in French]. J Pharm Belg 1991;46:165-76.
113. Bos R, Woerdenberg HJ, De Smet PAGM, Scheffer JJC. Valeriana species. In: De Smet PAGM, Keller K, Hänsel R, Chandler RF, editors. Adverse effects of herbal drugs, volume 3. Berlin: Springer-Verlag; 1997. p. 165-80.
114. Willey LB, Mady SP, Cobaugh DJ, Wax PM. Valerian overdose: a case report. Vet Hum Toxicol 1995;37:364-5.
115. Garges HP, Varia I. Doraiswamy PM. Cardiac complications and delirium associated with valerian root withdrawal. JAMA 1998;280:1566-7.
116. Bottiglieri T. Folate, vitamin B12, and neuropsychiatrie disorders. Nutr Rev 1996;54:382-90.
117. Crellin R, Bottiglieri T, Reynolds EH. Folates and psychiatric disorders: clinical potential. Drugs 1993;45:623-36.
118. Godfrey PS, Toone BK, Carney MW, Flynn TG, Bottiglieri T, Laundy M, Chanarin I, Reynolds EH. Enhancement of recovery from psychiatric illness by methylfolate. Lancet 1990;336:392-5.
119. Bottiglieri T, Hyland K, Laundy M, Godfrey P, Carney MW, Toone BK, Reynolds EH. Folate deficiency, biopterin and monoamine metabolism in depression. Psychol Med 1992;22:871-6.
120. Reynolds EH. Interrelationships between the neurology of folate and vitamin B12 deficiency. In: Folic acid in neurology, psychiatry, and internal medicine. New York: Raven Press; 1979. p. 501-15.
121. Thornton WE, Thornton BP. Geriatric mental function and serum folate: a review and survey. South Med J 1977;70:919-22.
122. Abalan F, Subra G, Picard M, Boueilh P. Incidence of vitamin B12 and folic acid deficiencies on old aged psychiatric patients [in French]. Encephale 1984;10:9-12.
123. Reynolds EH, Carney MW, Toone BK. Methylation and mood. Lancet 1984;2:196-8.
124. Hutto BR. Folate and cobalamin in psychiatric illness. Compr Psychiatry 1997;38:305-14.
125. Fava M, Borus JS, Alpert JE, Nierenberg AA, Rosenbaum JF, Bottiglieri T. Folate, vitamin B12, and homocysteine in major depressive disorder. Am J Psychiatry 1997;154:426-8.
126. Coppen A, Chaudhry S, Swade C. Folic acid enhances lithium prophylaxis. J Affect Disord 1986;10:9-13.
127. Furst DE. Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. Br J Rheumatol 1995;34(Suppl 2):20-5.
128. Reynolds EH. Mental effects of anticonvulsants and folic acid metabolism. Brain 1968;91:197-214.
129. Coppen A, Swade C, Jones SA, Armstrong RA, Blair JA, Leeming RJ. Depression and tetrahydrobiopterin: the folate connection. J Affect Disord 1989;16:103-7.
130. Curtius HC, Niederwieser A, Levine RA, Lovenberg W, Woggon B, Angst J. Successful treatment of depression with tetrahydrobiopterin. Lancet 1983;1:657-8.
131. Bottiglieri T, Hyland K, Reynolds EH. The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. Drugs 1994;48:137-52.
132. Janicak PG, Lipinski J, Davis JM, Altman E, Sharma RP. Parenteral S-adenosyl-methionine (SAMe) in depression: literature review and preliminary data. Psychopharmacol Bull 1989;25:238-42.
133. Kagan BL, Sultzer DL, Rosenlicht N, Gerner RH. Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 1990;147:591-5.
134. Bressa GM. S-Adenosyl-L-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl 1994;154:7-14.
135. Fava M, Giannelli A, Rapisarda V, Patralia A, Guaraldi GP. Rapidity of onset of the antidepressant effect of parenteral S-adenosyl-L-methionine. Psychiatry Res 1995;56:295-7.
136. Carney MW, Chary TK, Bottiglieri T, Reynolds EH. The switch mechanism and the bipolar/unipolar dichotomy. Br J Psychiatry 1989;154:48-51.
137. Moller SE, Kirk L, Honore P. Relationship between plasma ratio of tryptophan to competing amino acids and the response to L-tryptophan treatment in endogenously depressed patients. J Affect Disord 1980;2:47-59.
138. Young SN, Teff KL. Tryptophan availability, 5HT synthesis and 5HT function. Prog Neuropsychopharmacol Biol Psychiatry 1989;13:373-9.
139. van Praag HM. Management of depression with serotonin precursors. Biol Psychiatry 1981;16:291-310.
140. van Praag HM, Lemus C, Kahn R. The pitfalls of serotonin precursors as challengers in hormonal probes of central serotonin activity. Psychopharmacol Bull 1986;22:565-70.
141. Hippius H, Matussek N. Remarks on the therapy of depressions with amine precursors. Psychopathology 1986;19(Suppl 2):132-5.
142. Walinder J, Skott A, Carlsson A, Nagy A, Bjorn-Erik R. Potentiation of the antidepressant action of clomipramine by tryptophan. Arch Gen Psychiatry 1976;33:1384-9.
143. Smith KA, Fairburn CG, Cowen PJ. Relapse of depression after rapid depletion of tryptophan. Lancet 1997;349:915-9.
144. Neumeister A, Praschak-Rieder N, Hesselmann B, Vitouch O, Rauh M, Barocka A, Kasper S. Effects of tryptophan depletion in fully remitted patients with seasonal affective disorder during summer. Psychol Med 1998;28:257-64.
145. Neumeister A, Turner EH, Matthews JR, Postolache TT, Barnett RL, Rauh M, Vetticad RG, Kasper S, Rosenthal NE. Effects of tryptophan depletion vs catecholamine depletion in patients with seasonal affective disorder in remission with light therapy. Arch Gen Psychiatry 1998;55:524-30.
146. Sandyk R. L-Tryptophan in neuropsychiatricdisorders: a review. Int J Neurosci 1992;67:127-44.
147. Anonymous. 5-Hydroxytryptophan. Altern Med Rev 1998;3:224-6.
148. Byerley WF, Judd LL, Reimherr FW, Grosser BI. 5-Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects. J Clin Psychopharmacol 1987;7:127-37.
149. Hertzman PA, Blevins WL, Mayer J, Greenfield B, Ting M, Gleich GJ. Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. N Engl J Med 1990;322:869-73.
150. Ciraulo DA, Shader RI, Greenblatt DJ, Creelman W, editors. Drug interactions in psychiatry. 2nd ed. Baltimore: Williams and Wilkins; 1995.
151. Brennan D, MacManus M, Howe J, McLoughlin J. 'Neuroleptic malignant syndrome' without neuroleptics. Br J Psychiatry 1988;152:578-9.
152. Staufenberg EF, Tantam D. Malignant hyperpyrexia syndrome in combined treatment. Br J Psychiatry 1989;154:577-8.
153. Steiner W, Fontaine R. Toxic reaction following the combined administration of fluoxetine and L-tryptophan: five case reports. Biol Psychiatry 1986;21:1067-71.
154. Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol 1997;17:208-21.
155. Price WA, Zimmer B. Effect of L-tryptophan on electroconvulsive therapy seizure time. J Nerv Ment Dis 1985;173:636-8.
156. Alino JJ, Gutierrez JL, Iglesias ML. 5-Hydroxytryptophan (5-HTP) and a MAOI (nialamide) in the treatment of depressions: a double-blind controlled study. Int Pharmacopsychiatry 1976;11:8-15.
157. Nardini M, De Stefano R, lannuccelli M, Borghesi R, Battistini N. Treatment of depression with L-5-hydroxytryptophan combined with chlorimipramine, a double-blind study. Int J Clin Pharmacol Res 1983;3:239-50.
158. Michelson D, Page SW, Casey R, Trucksess MW, Love LA, Milstien S, Wilson C, Massaquoi SG, Crofford LJ, Hallett M, Gold PW, Sternberg EM. An eosinophilis-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan. J Rheumatol 1994;21:2261-5.
159. Williamson BL, Klarskov K, Tomlinson AJ, Gleich GJ, Naylor S. Problems with over-the-counter 5-hydroxy-L-tryptophan. Nature Med 1998;4:983.
160. Gelenberg AJ, Wojcik JD, Gibson CJ, Wurtman RJ. Tyrosine for depression. J Psychiatr Res 1982;17:175-80.
161. Sabelli HG, Fawcett J, Gusovsky F, Javaid JI, Wynn P, Edwards J, Jeffriess H, Kravitz H. Clinical studies on the phenylethylamine hypothesis of affective disorder: urine and blood phenylacetic acid and phenylalanine dietary supplements. J Clin Psychiatry 1986;47:66-70.
162. Gelenberg AJ, Wojcik JD, Falk WE, Baldessarini RJ, Zeisel SH, Schoenfeld D, Mok GS. Tyrosine for depression: a double-blind trial. J Affect Disord 1990;19:125-32.
163. Sabelli HC, Javaid JI. Phenylethylamine modulation of affect: therapeutic and diagnostic implications. J Neuropsychiatry Clin Neurosci 1995;7:6-14.
164. Mahadik SP, Evans DR. Essential fatty acids in the treatment of schizophrenia. Drugs Today 1997;33:5-17.
165. Hibbeln JR, Palmer JW, Davis JM. Are disturbances in lipid-protein interactions by phospholipase-A2 a predisposing factor in affective illness? Biol Psychiatry 1989;25:945-61.
166. Hibbeln JR, Salem N Jr. Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy. Am J Clin Nutr 1995;62:1-9.
167. Hillbrand M, Spitz RT, VandenBos GR. Investigating the role of lipids in mood, aggression, and schizophrenia. Psychiatr Serv 1997;48:875-6.
168. Hibbeln JR, Umhau JC, George DT, Salem N Jr. Do plasma polyunsaturates predict hostility and depression? World Rev Nutr Diet 1997;82:175-86.
169. Buajordet I, Madsen S, Olsen H. Statins - the pattern of adverse effects with emphasis on mental reactions: data from a national and an international database. Tidsskr Nor Laegeforen 1997;117:3210-3.
170. Hibbeln JR, Linnoila M, Umhau JC, Rawlings R, George DT, Salem N Jr. Essential fatty acids predict metabolites of serotonin and dopamine in CSF among healthy controls, early and late onset alcoholics. Biol Psychiatry 1998;15:44:235-42.
171. Hibbeln JR, Umhau JC, Linnoila M, George DT, Ragan PW, Shoaf SE, Vaughan MR, Rawlings R, Salem N Jr. A replication study of violent and nonviolent subjects: CSF metabolites of serotonin and dopamine are predicted by plasma essential fatty acids. Biol Psychiatry 1998;15:44:243-9.
172. Peet M, Murphy B, Shay J, Horrobin D. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry 1998;43:315-9.
173. Stoll AL, Severus E, Freeman MP, Rueter S, Zboyan HA, Diamond E, Cress KK, Marangell LB. Omega-3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999;56:380-1.